Member Info for Soupdragon78

Redx showing how it works, picking up a £9m milestone payment today for initiation of phase 1.

Looks like Brindley finished up last week on the 16th, so over to Riddell now.

Blood ninja, it wasn’t lack of interest, it was that they couldn’t have a placing given the last one was only in March. Do pay attention.

Bodruncie,

VRS lanstead deal done on 23 March 2020, shareprice was at 32p, subscription was at 40p.
Price then rose up to 70p following this then peaked near 80p. So again no drag there.
Dropped back down to current 25p on doubling of yearly losses.

It’s possible whimax, although all down to Lansteads cash flow, I’m sure they don’t want to be using their own cash at risk.

Wassap, the dilution is set and won’t change so that’s not an issue. It just means they don’t get as much as expected. But both parties don’t benefit as much as the could do so it’s not one sided.

Using the first tranche as the basis of the Calcs.

Lanstead get 22m shares at 1.5p each and an agreement to pay NFX £330k in 4 equal payments if a set price of 2p is met. This means NFX get £82,500 each month at that strike price sp.

So, if the sp sat on the agreement price of 2p for the entire time.
Lanstead would sell 5.5m shares each month to release the equity.

So selling 5.5m at 2p would net £110,000 with £82,500 going to NFX, leaving profit of £27,500 to Lanstead.

If the sp was 1p then selling 5.5m would net £55,000 with £41,250 going to NFX, leaving Lanstead with only £13,750 to bank.

If the sp was 4p then NFX would get £165,000 and Lanstead bank £55,000.

Clearly in their interest to see an higher sp.
also because of the additional shares they hold.

When you work through the numbers, it’s in Lansteads interests for the sp to be at the agreement price of 2p rather than here. They make approx twice as much at that price than down here.

Whimax, they were given the additional 2m as their sweetener. Ensures they don’t lose money.

“ The Company will pay Lanstead's legal costs incurred in the Subscription and in entering into the Sharing Agreements and, in addition, has agreed to issue to Lanstead 2,000,000 new Ordinary Shares (the "First Value Payment Shares") in connection with entering into the First Sharing Agreement and 5,700,000 shares in connection with entering into the Second Sharing Agreement (the "Second Value Payment Shares"). The Second Value Payment Shares are expected to be issued in April 2022 at the same time as the issuance of the Second Subscription Shares.”

Maybe Riddells plan is to appoint the (unelected) former Brexit minister David Frost as business development chap, after all he was stupid enough to believe in Johnson, he’d be willing to take on this thankless task.

SSM, in all fairness the half years were on track for revenues as they are as predicted by the July Allenby report.

Yes they are low, but this is an R&D company not a monthly revenue generator.

Didn't you know, that minus symbol in front of the numbers on your account is the secret new world order symbol for 'profit', something to do with the Rothschilds I heard.

In my infinite naivety, I scratching my head as to why mm's would allow so many sells, at the minute theres been about 3m more sells than buys. Surely they don't want to be sat on those too long given the trajectory?

JJW, I know what I want it to be, what the shareprice will do in reality I haven't a clue like everyone else.

I would never have expected it to be where it is today, given it started the year at 3p.

All I'm focussed on is that if they get all the packages together with strong data, then there is a very good chance its worth more than the current 6m mcap.

No dilemma, I see this as being more valuable than that.

Lol Chab, I was going to go for a headstone with 'Deal imminent' on it!

lol chab, fair enough, maybe if we all buy more then the results will come back quicker! First one to buy a million gets the durability results on xmas eve!

You know what I mean though.

chab, science isn't emotive in such a way, the success of the tests isn't linked to share ownership.

In my view, they have made huge progress this past year bringing NXP002 to a point of evidential proof of concept. This is the point it starts to move forward.

Chab, unfortunately nobody here can answer that, only the BoD themselves. So a bit of a fruitless question for people to keep putting forward.

At the end of the day, you can always find a 'why aren't they doing this?' aspect to everything.

Regardless of whether the board are buying or not, do you think that an inhaler feasibility package for a drug with potential to distrupt a large market is worth more than £6m to a drug company or not?